Avalo Therapeutics Files 8-K
Ticker: AVTX · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1534120
| Field | Detail |
|---|---|
| Company | Avalo Therapeutics, INC. (AVTX) |
| Form Type | 8-K |
| Filed Date | Jan 13, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing, financials
Related Tickers: AVTX
TL;DR
AVTX filed an 8-K, mostly standard financial docs, no major news.
AI Summary
On January 13, 2025, Avalo Therapeutics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no specific material events or other significant business updates detailed in the provided text.
Why It Matters
This filing indicates Avalo Therapeutics is submitting required financial and exhibit information to the SEC, which is standard procedure for public companies.
Risk Assessment
Risk Level: low — The filing appears to be routine and does not disclose any new material events, risks, or significant financial changes.
Key Players & Entities
- Avalo Therapeutics, Inc. (company) — Registrant
- Cerecor Inc. (company) — Former company name
- January 13, 2025 (date) — Date of earliest event reported
FAQ
What is the primary purpose of this 8-K filing for Avalo Therapeutics?
The primary purpose of this 8-K filing is to report financial statements and exhibits as of January 13, 2025.
What was Avalo Therapeutics' former company name?
Avalo Therapeutics, Inc.'s former company name was Cerecor Inc.
In which state was Avalo Therapeutics incorporated?
Avalo Therapeutics, Inc. was incorporated in Delaware.
What is the principal executive office address for Avalo Therapeutics?
The principal executive office address for Avalo Therapeutics is 540 Gaither Road, Suite 400, Rockville, Maryland 20850.
What is the IRS Employer Identification Number for Avalo Therapeutics?
The IRS Employer Identification Number for Avalo Therapeutics is 45-0705648.
Filing Stats: 422 words · 2 min read · ~1 pages · Grade level 11 · Accepted 2025-01-13 07:07:18
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 Par Value AVTX Nasdaq Capital Market
Filing Documents
- avtx-20250113.htm (8-K) — 25KB
- ex-991_avalocorporatepre.htm (EX-99.1) — 31KB
- ex-991_avalocorporatepre001.jpg (GRAPHIC) — 93KB
- ex-991_avalocorporatepre002.jpg (GRAPHIC) — 152KB
- ex-991_avalocorporatepre003.jpg (GRAPHIC) — 138KB
- ex-991_avalocorporatepre004.jpg (GRAPHIC) — 132KB
- ex-991_avalocorporatepre005.jpg (GRAPHIC) — 122KB
- ex-991_avalocorporatepre006.jpg (GRAPHIC) — 151KB
- ex-991_avalocorporatepre007.jpg (GRAPHIC) — 49KB
- ex-991_avalocorporatepre008.jpg (GRAPHIC) — 146KB
- ex-991_avalocorporatepre009.jpg (GRAPHIC) — 125KB
- ex-991_avalocorporatepre010.jpg (GRAPHIC) — 135KB
- ex-991_avalocorporatepre011.jpg (GRAPHIC) — 138KB
- ex-991_avalocorporatepre012.jpg (GRAPHIC) — 129KB
- ex-991_avalocorporatepre013.jpg (GRAPHIC) — 178KB
- ex-991_avalocorporatepre014.jpg (GRAPHIC) — 158KB
- ex-991_avalocorporatepre015.jpg (GRAPHIC) — 175KB
- ex-991_avalocorporatepre016.jpg (GRAPHIC) — 175KB
- ex-991_avalocorporatepre017.jpg (GRAPHIC) — 64KB
- ex-991_avalocorporatepre018.jpg (GRAPHIC) — 43KB
- ex-991_avalocorporatepre019.jpg (GRAPHIC) — 182KB
- ex-991_avalocorporatepre020.jpg (GRAPHIC) — 35KB
- ex-991_avalocorporatepre021.jpg (GRAPHIC) — 138KB
- ex-991_avalocorporatepre022.jpg (GRAPHIC) — 37KB
- ex-991_avalocorporatepre023.jpg (GRAPHIC) — 30KB
- ex-991_avalocorporatepre024.jpg (GRAPHIC) — 111KB
- 0001628280-25-001228.txt ( ) — 4096KB
- avtx-20250113.xsd (EX-101.SCH) — 2KB
- avtx-20250113_lab.xml (EX-101.LAB) — 21KB
- avtx-20250113_pre.xml (EX-101.PRE) — 12KB
- avtx-20250113_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On January 13, 2025, Avalo Therapeutics, Inc. (the "Company") posted on its website an updated investor presentation (the "Investor Presentation"). The Investor Presentation will be used from time to time in meetings with investors. A copy of the Investor Presentation is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits: Exhibit No. Description 99.1 Investor Presentation . 104 The cover pages of this Current Report on Form 8-K, formatted in Inline XBRL. 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AVALO THERAPEUTICS, INC. Date: January 13, 2025 By: /s/ Christopher Sullivan Christopher Sullivan Chief Financial Officer 2